Doctors track Real-World results of new prostate cancer treatment

NCT ID NCT06514521

Summary

This study is observing how well the approved prostate cancer drug Pluvicto works and what side effects patients experience in real-world medical practice in South Korea. It will follow about 278 adult men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers will track side effects and how the cancer responds to treatment, but this is an observational study where patients receive the drug as part of their normal care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeonggi-do, Korea, 10408, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 110-744, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 139-706, South Korea

Conditions

Explore the condition pages connected to this study.